NewAmsterdam Pharma Company N.V. (NAMS) Financials

NAMS Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 732.6 million 67.4 million
Dec. 31, 2025 769.3 million 85.9 million
Sept. 30, 2025 786.4 million 58.4 million
June 30, 2025 815.1 million 36.6 million

NAMS Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -30.6 million ?
Dec. 31, 2025 -41.0 million 14.0 million
Sept. 30, 2025 -32.8 million 15.0 million
June 30, 2025 -37.8 million 15.2 million

NAMS Net Income

No data available :(

NAMS Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 636.1 million - -
Dec. 31, 2025 636.2 million 66000 202000
Sept. 30, 2025 702.9 million 85000 266000
June 30, 2025 739.2 million - 328000

NAMS Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 121.1 million
Dec. 31, 2025 114.4 million
Sept. 30, 2025 119.0 million
June 30, 2025 112.5 million

NAMS Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 38000 37.5 million 23.5 million -
Dec. 31, 2025 100000 38.6 million 27.4 million -
Sept. 30, 2025 42000 31.0 million 24.5 million -
June 30, 2025 88000 27.5 million 27.3 million -

NAMS Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 3.0 million 500000
Dec. 31, 2025 32000 59000
Sept. 30, 2025 348000 64000
June 30, 2025 19.1 million 45000

NAMS

Price: $30.60

52 week price:
17.63
42.21

Earnings Per Share: -1.78 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 3.7 billion

Links: